Retrotope

Retrotope

Retrotope has created a new category of drug platform to preserve and restore mitochondrial health in degenerative diseases. The unique mechanism of Retrotope’s platform prevents cellular damage and recovers cellular function damaged by lipid peroxidation due to oxidative stress.

Related Articles & Links

September 15, 2016 Retrotope announces Phase I/II Clinical Trial Results of RT001 in Treatment of Friedreich’s ataxia

June 1, 2016: US FDA Grants Orphan Drug Designation for Retrotope’s RT001 in the treatment of Friedreich’s ataxia. First-in-human clinical trial for RT001 is now fully enrolled.

August 17, 2015: Retrotope announces open enrollment for Friedreich’s ataxia clinical trial

April 19, 2015: Retrotope appoints Dr. Ernst-Guenter Afting to its Board of Directors as it enters clinical stage.

March 31, 2015: Retrotope appoints Dr. Peter Milner to its Board of Directors as it enters clinical stage.

March 30, 2015: Retrotope presents at the International Ataxia Research Conference in Windsor, UK.

January 15, 2015: Retrotope closes $10M Series B financing.

January 15, 2015: Retrotope announces publication of results for a Parkinson’s Disease Model.

December 9, 2014: Retrotope announces the issuance of new patents.

November 13, 2014: Retrotope appoints Dr. Harry J. Saal as Chairman of the Board of Directors.

Our Philosophy

We focus on portfolio returns, big opportunities, high-quality team, and financials that demonstrate a deep understanding of the business. We look for companies where our experience and expertise can add value to produce better outcomes for both entrepreneurs and our investments.

Our Networks

Relationships and people matter. Over the decades, we have developed personal relationships with other quality investors (both Angels and VCs), service providers, and domain experts. If we do not know the answer, we know someone who does.

Our Mentorship

When the company wins, we all win. To maximize success, we often serve as advisors or board members. Both art and science are involved in building a supportive and useful board as well as maintaining solid investor relations. Good financial discipline lays the foundation for success and informs company strategy.

Our Strategy

We like healthcare, especially digital health, but also diagnostics, devices, and bio/genomics. For funding, we often co-invest with other investors and are happy to lead investment rounds. We know term sheets and what drives syndicated investment rounds.
Scroll to top